Efficacy and Safety of Using MPC-5971 in Subjects Undergoing Shock Wave Lithotripsy

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Nephrolithiasis

In brief

The purpose of this study is to evaluate the efficacy of MP-5971 in facilitating stone passage after Shock Wave Lithotripsy treatment.

Key facts

Study ID

NCT00860093

Run by

Mission Pharmacal

People needed

135

Starts

2010-04-01

Expected to finish

2010-12-01

Last updated by the study team

2019-03-07

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female subject aged > or equal to 18 to < or equal to 70.
• Subject has undergone a computerized tomography (CT) scan within 30 days of the screening visit.
• Subject has been diagnosed with single unilateral renal calculus (target treatment stone).
• Target treatment stone, is presumed to be of calcium composition and/or uric acid composition.
• Target treatment stone is between > or equal to 5 and < or equal to 15 mm in diameter.
• Contra lateral kidney may hold a clinically inconsequential size calculus that does not require concurrent SWL treatment.
• Both kidneys are anatomically normal.
• An appropriate candidate for SWL, determined by treating physician.
• Female subjects with a negative pregnancy test, hysterectomy, tubal ligation or non-child bearing potential (post-menopausal).
• Female subjects of child bearing potential with a negative pregnancy test and taking appropriate birth control for the duration of the study.
• Urine is pyuria negative and nitrite negative on dipstick and/or negative upon microscopic evaluation.
• Subject must voluntarily consent to participate in this study and provide his/her written informed consent prior to start of any study-specific procedures.

You may not qualify if…

• Current or past history of cystine stones or infection stones.
• Renal insufficiency, defined as serum creatinine value outside of the normal reference range.
• Currently has or had hyperkalemia within the past six months, defined as serum potassium outside of the normal reference range.
• Currently has or had hypermagnesemia within the past six months, defined as serum magnesium outside of the normal reference range.
• Active urinary tract infection.
• Renal calculi in an anatomically abnormal kidney; horseshoe shape, ureteropelvic junction obstruction or calyceal diverticulum.
• Altered urinary tract anatomy such as a transplant kidney, urinary reconstruction or congenital anomaly.
• Blood coagulopathies and or taking anticoagulants (warfarin, coumarin, heparin).
• Taking salicylate (aspirin), including low dose aspirin for cardio-prophylaxis or other NSAID (OTC) that may increase bleeding time, within the past 7 days.
• History of complications with previous SWL; pyelonephritis, perinephric hematoma.
• Unsuccessful SWL treatments for previous stone within the past six months.
• Currently has or previously had ulcers of the esophagus, stomach and/or small intestines.
• Chronic diarrhea or has a history of diarrhea.
• Bowel disease such as Crohn's disease, Celiac disease, fat malabsorption or Sprue.
• Undergone any bariatric surgery procedures.
• Obese, defined as BMI >30.
• Uncontrolled hypertension defined as subjects taking medication specific for hypertension or subject not on medication with systolic blood pressure above 140 and diastolic above 90.
• Adrenal insufficiency (i.e., Addison's disease), adrenal tumors, and/or subjects on adrenal hormone replacement therapy.
• Taking potassium-sparing diuretics (triamterene, amiloride, spironolactone, Midamor®, Aldactone®, Dyrenium®, Eplerenone®).
• Taking potassium supplements (Rx or OTC) within the past 15 days.
• Taking magnesium supplements (Rx or OTC) within the past 15 days.
• Taken potassium citrate supplements (Rx or OTC) within the past 30 days.
• Subject taking anticholinergic medications at entry (dicyclomine, atropine, scopolamine, oxybutynin, tolerodine, Cogentin®, Sinemet®, Robinal®, Kenadrin®, Artane®, Enablex®, Detrol®, Vesicare®, Sanctura®, Ditropan®, Oxytrol®, Bentyl®, Byclomine®, Dibent®, Di-Spaz®, or Dilomine®). (Subjects may be prescribed anticholinergics as standard of care with use of stents post entry.)
• Subject is has taken gastrointestinal enzyme replacement therapy or proton pump inhibitors within past 30 days (Ultrase®, Creon®, Viokase®, Pancrease® MT, pancrelipase agents, Aciphex®, Nexium®, Prevacid®, Protonix®, Zegerid® Prilosec OTC®, Kapidex®, rabeprazole, esomeprazole, lansoprazole, pantoprazole, omeprazole, dexlansoprazole).
• Women who are pregnant or lactating.

Where it is running

• Idaho Urologic Institute — Meridian, Idaho, United States
• Columbus Urology Research — Columbus, Ohio, United States
• Urology Clinics of North Texas, PA — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.